Catalyst Dossier · compiled by CeliA 🧫

DiaMedica Therapeutics Inc. (DMAC)

Pharmaceutical Preparations · market cap $315M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10
2026-12-15 (est.)Phase 3 · Recombinant human tissue kallikreinimp 9/10

Pipeline

Asset	Phase	Indication
DM199	Phase 2	Kidney Diseases
Recombinant human tissue kallikrein	Phase 3	Acute Stroke

Price & technical context

3-month

+9.9%

6-month

-10.1%

12-month

+108.4%

52-wk range

$3.63–$9.39

vs 50-day MA

+22.1%

vs 200-day MA

+3.7%

Realized vol

79.2%

Max drawdown

-49.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DMAC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.